Perioperative Granulocyte Colony-Stimulating Factor Does Not Prevent Severe Infections in Patients Undergoing Esophagectomy for Esophageal Cancer

Abstract

Perioperative administration of G-CSF failed to reduce postoperative morbidity, infection rate, or mortality in patients with esophageal cancer who underwent esophagectomy.

Immune response of severely injured patients – influence of surgical intervention and therapeutic impact

“…A larger controlled trial (n=153 total) with G-CSF given perioperatively in patients undergoing esophagectomy was not able to confirm these results. The rate of infection and 20-day mortality was identical in both groups [81]. Prophylactic G-CSF therapy in patients with cerebral hemorrhage or blunt brain injury caused a dosedependent increase of neutrophil counts; however, the frequency of nosocomial infections did not differ from the placebo group [82].…”

Application of Adaptive Designs – a Review

“…5. In this two-armed randomized, placebo controlled multi-centre clinical trial (Schaefer et al, 2004) it has been investigated if a new treatment is able to reduce a proportion of events. "The trial was planned according to the 2-stage Bauer and Kaehne adaptive method, which combines the 2 p-values of the separate stages with Fisher's combination test.…”

Sickness behavior of rats with abdominal sepsis can be improved by antibiotic and G-CSF prophylaxis in clinic modeling randomized trials

“…For this reason, G-CSF is a promising immune modulator for normalization of these parameters [54,55]. However in the treatment of patients with pneumonia [56] and as prophylaxis in patients with esophageal resections [57] G-CSF was not effective.…”